Completed PHASE2 INTERVENTIONAL 2-arm NCT01086254

SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer

Randomized Phase 2 Study of Gemcitabine/Cisplatin With or Without SAR240550 (BSI-201), a PARP1 Inhibitor, in Patients With Stage IV Non-small Cell Lung Cancer

Sponsor: Sanofi

Conditions Non-small Cell Lung Cancer Stage IV

Interventions Iniparib cisplatin gemcitabine

Updated 7 times since 2017 Last updated: Sep 23, 2013 Started: May 31, 2010 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01086254, this PHASE2 trial focuses on Non-small Cell Lung Cancer Stage IV and remains completed. Sponsored by Sanofi, it has been updated 7 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Badalona, Spain , Barcelona, Spain , Caen, France , Essen, Germany , Gauting, Germany , Großhansdorf, Germany , Livorno, Italy , Marseille, France , Newcastle upon Tyne, United Kingdom , Orbassano, Italy and 4 more locations